Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Orthopedic MIS Comes of Age

Executive Summary

Minimally invasive surgeries, once predicted to replace open surgeries across the board, have never taken off to a great degree, because MIS required more intricate and demanding manipulations that were uncomfortable, if not outright impossible for surgeons. It is against this background of MIS's stalled success that the adoption of minimally invasive techniques in that most unlikely of surgical specialties, orthopedics, and in particular, hip and knee joint replacements, is most amazing. A half decade after the introduction of the first true MIS procedures in total hip replacement, orthopedic surgeons have continued to push penetration rates of MIS well beyond what anyone might have expected.

You may also be interested in...



Joint Resurfacing: Boom or Bust?

One of the hottest topics at the 2007 AAOS was the the trend toward resurfacing rather than completely replacing joints damaged by arthritis and other causes. There are a variety of metallic, synthetic and biologic methods used in hip, knee, shoulder and extremity joint resurfacing, many designed for younger patients who wish to remain active and avoid total joint replacement.

Clinical Update (03/2007)

Recent clinical developments in the medical device industry, including developments in Artificial Limbs, Tissue-Engineered Therapy for ACL Tears, using Genes to Identify Early Atherosclerosis, and Stem Cell News.

Encore Medical Goes Private

Despite significant growth over the past several years, Encore Medical found it difficult to win over investors. So it has turned to private equity firm Blackstone Group to take it private, hoping that greater financial freedom will enable it to continue its aggressive growth.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT035012

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel